Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and Hepatitis C coinfection

AIDS Research and Human Retroviruses

Volumn 31, Issue 2, 2015, Pages 189-197

  Patel, Nimish ^a   Nasiri, Mona ^a   Koroglu, Arden ^a   Amin, Ronish ^a   Mcguey, Liam ^a   Mcnutt, Louise Anne ^b   Roman, Martha ^c   Miller, Christopher ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; COBICISTAT; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEUROLEPTIC AGENT; NEVIRAPINE; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; RITONAVIR; SAQUINAVIR; SIMEPREVIR; SOFOSBUVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ANTIVIRUS AGENT; FUSED HETEROCYCLIC RINGS; SULFONAMIDE; URIDINE PHOSPHATE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SUBSTANCE ABUSE; ANALOGS AND DERIVATIVES; COINFECTION; COMPLICATION; DRUG INTERACTION; HEPATITIS C, CHRONIC; HIV INFECTIONS; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; COINFECTION; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; FEMALE; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SULFONAMIDES; URIDINE MONOPHOSPHATE;

EID: 84923248222     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0215     Document Type: Article

References (18)

1. Olysio (simeprevir) tablet package insert. Janssen Therapeutics, Division of Janssen Products, LP, Titusville, NJ, 2013.
2. Sovaldi (sofosbuvir) package insert. Gilead Sciences, Foster City, CA, 2013.
3. Kowdley KV, Lawitz E, Crespo I, et al.: Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatmentnaive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial. Lancet 2013;381(9883):2100-2107.
4. Fried MW, Buti M, Dore GJ, et al.: Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: The randomized PILLAR study. Hepatology 2013;58(6):1918-1929.
5. Tedaldi EM, Hullsiek KH, Malvestutto CD, et al.: Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: The Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 2003;36(10): 1313-1317.
6. Klein MB, Lalonde RG, and Suissa S: The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003;33(3):365-372.
7. Al-Mohri H, Murphy T, Lu Y, et al.: Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007;44(4):463-469.
8. Linas BP, Wang B, Smurzynski M, et al.: The impact of HIV/HCV co-infection on health care utilization and disability: Results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat 2011;18(7): 506-512.
9. Recommendations for Testing, Managing, and Treating Hepatitis C: American Association for the Study of Liver Diseases/Infectious Diseases Society of America, with International Antiviral Society-USA. www.hcvguidelines.org/full-report-view. Accessed August 8, 2014.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/.contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed August 8, 2014.
11. Jimenez-Nacher I, Alvarez E, Morello J, et al.: Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol 2011;7(4):457-477.
12. Griffin L, Annaert P, and Brouwer KL: Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci 2011; 100(9):3636-3654.
13. Zdanowicz MM: The pharmacology of HIV drug resistance. Am J Pharm Educ 2006;70(5):100.
14. Johnson JA, Li JF, Wei X, et al.: Minority HIV-1 drug resistance mutations are present in antiretroviral treatmentnaive populations and associate with reduced treatment efficacy. PLoS Med 2008;5(7):e158.
15. Winnock M, Bani-Sadr F, Pambrun E, et al.: Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: Role of comorbidities and physicians' perceptions. HIV Med 2013;14(7):430-436.
16. Mountford CM, Lee T, de Lemos J, and Loewen PS: Quality and usability of common drug information databases. Can J Hosp Pharm 2010;63(2):130-137.
17. Up-To-Date, Inc. Lexi-interact online: Available from www.uptodate.com/crlsql/interact/frameset.jsp. Accessed August 11, 2014.
18. McNutt LA, Wu C, Xue X, and Hafner JP: Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003;157(10):940-943.